Generate a tailored SOP for Dr. Harriet Richardson. Improve your application with a focused, well-structured draft.
Dr. Harriet Richardson is an Associate Professor in the Department of Public Health Sciences at Queen's University. She serves as a Senior Investigator with the Canadian Cancer Trials Group and works within the Cancer Care Epidemiology Division at the Queen's Cancer Research Institute. Her research centers on the primary prevention of breast cancer, particularly in the context of clinical trials, where she evaluates the effects of anti-estrogen agents on breast cancer incidence and mammographic density. Dr. Richardson has authored significant publications, including a groundbreaking paper in the New England Journal of Medicine in June 2011 regarding exemestane and breast cancer prevention in postmenopausal women. She investigates the impact of aromatase inhibitors on quality of life and bone strength. Dr. Richardson is also engaged in projects related to biomarker development and the evaluation of quality of life data in clinical trials. Collaborating with colleagues from institutions such as the NIH, Washington State University, and the Mayo Clinic, she is exploring the role of genetic deletions in metabolic pathways associated with estrogen depletion. Furthermore, Dr. Richardson is involved in establishing reference ranges for postmenopausal estradiol levels and a cohort study evaluating the impact of COVID-19 on individuals living with cancer. She teaches courses in controlled clinical trials and environmental public health.
Department of Computing offers research-based, project-based, and course-based patterns.